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ORIGINAL ARTICLE
Maintenance of Clinical Efficacy and
Radiographic Benefit Through Two Years of
Ustekinumab Therapy in Patients With Active
Psoriatic Arthritis: Results From a Randomized,
Placebo-Controlled Phase III Trial
ARTHUR KAVANAUGH,1 LLUIS PUIG,2 ALICE B. GOTTLIEB,3 CHRISTOPHER RITCHLIN,4
SHU LI,5 YUHUA WANG,5 ALAN M. MENDELSOHN,5 MICHAEL SONG,5 YAOWEI ZHU,5
PROTON RAHMAN,6 AND IAIN B. MCINNES,7 ON BEHALF OF THE PSUMMIT 1 STUDY GROUP
Objective. To evaluate the efficacy and safety of ustekinumab through 2 years in adult patients with active psoriatic
arthritis (PsA).
Methods. A total of 615 adult patients with active PsA were randomized to placebo, ustekinumab 45 mg, or ustekinu-
mab 90 mg, at weeks 0, 4, and every 12 weeks through week 88 (last dose). At week 16, patients with <5% improvement
in both tender and swollen joint counts entered blinded early escape (placebo to 45 mg, 45 mg to 90 mg, and 90 mg to
90 mg). All remaining placebo patients crossed over to ustekinumab 45 mg at week 24. Clinical efficacy measures
included American College of Rheumatology criteria for 20% improvement (ACR20), Disease Activity Score in 28 joints
using the C-reactive protein level (DAS28-CRP), and ‡75% improvement in the Psoriasis Area and Severity Index
(PASI75). Radiographic progression was evaluated using the modified Sharp/van der Heijde score (SHS).
Results. At week 100, ACR20, DAS28-CRP moderate/good response, and PASI75 rates ranged from 56.7–63.6%, 71.9–76.7%,
and 63.9–72.5%, respectively, across the 3 treatment groups. In both ustekinumab groups, the median percent improvement in
dactylitis and enthesitis was 100% at week 100. The mean changes in SHS score from week 52 to week 100 were similar to
those observed from week 0 to week 52 in the ustekinumab groups. Through week 108, 70.7% and 9.7% of patients had an
adverse event (AE) or serious AE, respectively. The rates and type of AEs were similar between the dose groups.
Conclusion. Clinical and radiographic benefits from ustekinumab treatment were maintained through week 100 in the
PSUMMIT 1 study. No unexpected safety events were observed; the safety profile of ustekinumab in this population
was similar to that previously observed in psoriasis patients treated with ustekinumab.
INTRODUCTION
A considerable proportion of patients with psoriasis also
develop psoriatic arthritis (PsA) (1,2), which can affect
peripheral joints, the axial skeleton, and entheses and can
be associated with psoriatic skin and nail involvement (3).
Myriad consequences of this clinical constellation adverse-
ClinicalTrials.gov identifier: NCT01009086.
Supported by Janssen Research & Development.
1ArthurKavanaugh,MD:University of California, SanDiego,
La Jolla, California; 2Lluıs Puig, MD, PhD: Hospital de la Santa
Creu i Sant Pau, Universitat Autonoma de Barcelona, Barcelo-
na, Spain; 3Alice B. Gottlieb, MD, PhD: Tufts Medical Center,
Boston, Massachusetts; 4Christopher Ritchlin, MD, MPH: Uni-
versity of Rochester, Rochester, New York; 5Shu Li, PhD,
Yuhua Wang, PhD, Alan M. Mendelsohn, MD, Michael Song,
MD, Yaowei Zhu, PhD: Janssen Research & Development,
Spring House, Pennsylvania; 6Proton Rahman, MD, MSc:
Memorial University, St. John’s, Newfoundland and Labrador,
Canada; 7Iain B. McInnes, MD: University of Glasgow, Glas-
gow, Scotland.
Dr. Kavanaugh has received research support and consult-
ing fees, speaking fees, and/or honoraria (less than $10,000
each) from AbbVie, Amgen, Janssen, and UCB. Dr. Puig has
received research support and consulting fees, speaking fees,
and/or honoraria (less than $10,000 each) from AbbVie,
Amgen, Boehringer, Celgene, Eli Lilly, Janssen, Leo-Pharma,
Merck/Schering-Plough, Merck-Serono, Novartis, Pfizer, San-
doz, and VBL. Dr. Gottlieb has received research support (less
1739
ly impact patients’ physical function, work productivity,
and health-related quality of life (HRQOL) (3,4). PsA can be
effectively treated with disease-modifying antirheumatic
drugs (DMARDs) and biologic anti–tumor necrosis factor
(TNF) agents, yet not all patients respond to these modali-
ties. There is evidence that interleukin-23 (IL-23) may be
involved in the pathogenesis of psoriasis and PsA, thereby
providing an additional potential treatment target (5).
Ustekinumab, a monoclonal anti–IL-12/23p40 antibody,
is approved for the treatment of PsA and plaque psoriasis
(6). PSUMMIT 1 was one of two phase 3 trials of ustekinu-
mab in adults with active PsA (7). Through week 24 of
PSUMMIT 1, patients treated with ustekinumab had signif-
icantly greater overall improvements in joint- and skin-
related symptoms, physical function, dactylitis, and enthe-
sitis compared with placebo (7). An integrated analysis
with PSUMMIT 2 demonstrated significantly less radio-
graphic progression at week 24 for ustekinumab-treated
patients versus placebo (8). Clinical efficacy and inhibition
of radiographic progression were sustained through week
52 of PSUMMIT 1 (7,8). Here we report the final safety and
efficacy results from PSUMMIT 1 through 2 years.
PATIENTS AND METHODS
Patients and study design. The patient population and
study design of the randomized, placebo-controlled phase
3 PSUMMIT 1 trial were previously detailed (7). Briefly,
anti-TNF–naive adults with active PsA for $6 months pre-
viously treated with or intolerant to DMARDs ($3 months)
or nonsteroidal antiinflammatory drugs (NSAIDs; $4
weeks) were eligible. Patients were randomized to placebo,
ustekinumab 45 mg, or ustekinumab 90 mg at weeks 0 and
4 and every 12 weeks, with placebo crossover to ustekinu-
mab 45 mg at weeks 24 and 28, and every 12 weeks,
through week 88. At week 16, patients with ,5% improve-
ment in tender/swollen joint counts entered blinded early
escape (placebo to ustekinumab 45 mg; ustekinumab 45 mg
to 90 mg); patients randomized to ustekinumab 90 mg did
not have treatment adjustments. Continuation of concomi-
tant stable baseline doses of methotrexate (MTX), NSAIDs,
or oral corticosteroids was permitted. After week 52, adjust-
ments to concomitant medication doses and initiation of
other concomitant therapies were permitted.
PSUMMIT 1 was conducted according to the Declara-
tion of Helsinki. The protocol was approved by each site’s
institutional review board/ethics committee. All patients
gave written informed consent before any study-related
procedures were performed.
Assessments. Efficacy was assessed using the American
College of Rheumatology (ACR) criteria (9), the Disease
Activity Score in 28 joints using the C-reactive protein level
(DAS28-CRP), the Health Assessment Questionnaire (HAQ)
disability index (DI) (10), and the Psoriasis Area and Sever-
ity Index (PASI). The PASI scores the severity of psoriasis
on 4 regions (head, trunk, upper extremities, and lower
extremities) on a scale of 0–72, with lower scores indicating
less severe disease (11). Improvement in PASI $75%
(PASI75) is generally considered to be clinically meaningful,
and is a commonly used end point in trials of moderate-to-
severe psoriasis (12). The proportions of patients with 20%/
50%/70% improvement in ACR criteria (ACR20/50/70), a
good or moderate DAS28-CRP response (13), DAS28-CRP
remission (score ,2.6), and improvement in HAQ DI $0.30
were determined through week 100. PASI75 and PASI90
were assessed for patients with $3% body surface area
(BSA) affected by psoriasis at baseline.
Dactylitis was assessed in hands and feet using a sco-
ring system of 0–3 (05no dactylitis, 15mild dactylitis, 25
moderate dactylitis, and 35 severe dactylitis), as previously
described (14,15). Enthesitis was assessed using the
Maastricht Ankylosing Spondylitis Enthesitis Score (16),
modified for PsA (includes insertion of the plantar fascia).
HRQOL was evaluated using the Short Form 36 (SF-36)
health survey (11) physical and mental component summa-
ry (PCS and MCS, respectively) scores and the Dermatology
Life Quality Index (DLQI), a 10-item questionnaire (0–30
points) assessing the effect of skin disease on daily activi-
ties, leisure, work/school, and personal relationships (lower
scores indicate less impairment) (17).
Radiographic progression was scored using the modified
Sharp/van der Heijde score (SHS) with modifications for PsA,
including the addition of the distal interphalangeal joints in
Significance & Innovations
 Improvements in the signs and symptoms of psoriat-
ic arthritis and inhibition of radiographic progression
were maintained through 2 years of ustekinumab
therapy in adult patients with active disease.
 No unexpected safety events were observed through
2 years, and results were consistent with the known
safety profile of ustekinumab.
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both hands and the assessment of pencil-in-cup and gross
osteolysis features (maximum score5 528) (8,18). Scores
from radiographs of the hands and feet (weeks 0, 24, 52, and
100) were averaged from 2 independent readers, or an adjudi-
cator if required (8), blinded to time point, patient identity,
and treatment assignment. Through week 52, radiographic
data from PSUMMIT 1 were combined with data from PSUM-
MIT 2 in a prespecified integrated analysis (8). The current
analysis includes only data from PSUMMIT 1 from radio-
graphs at weeks 0, 52, and 100; radiographs from weeks 0 and
52 were re-read as specified in the protocol.
Safety assessments were performed through week 108.
Serum samples were collected through week 88 for measure-
ment of serum ustekinumab concentrations, and through
week 108 for evaluation of antibodies to ustekinumab.
Statistical analysis. Efficacy end points were analyzed
by randomized treatment group using treatment failure
rules that were previously applied through week 52 (7).
Briefly, for clinical efficacy and HRQOL analyses, patients
who discontinued treatment due to lack of efficacy or an
adverse event (AE) of worsening of disease, or initiated
treatment with prohibited medications, were classified as
nonresponders for binary end points and assigned zero
change for continuous variables at subsequent time points.
DMARDs, other than MTX, systemic immunosuppressives,
or additional corticosteroids were not considered to be pro-
hibited therapies after week 52. No treatment group com-
parisons were performed after week 24. In the placebo
crossover group, only ustekinumab-treated patients were
included in efficacy analyses after week 24.
Missing radiographic scores between week 52 and 100
were imputed using linear extrapolation if the patient had
scores at 2 time points from week 52 to 100. Otherwise,
the missing value was replaced with the median of the
change in the total scores from all patients within the
same MTX stratification at the missing time point.
Subgroup analyses explored efficacy by early escape sta-
tus, weight group (# or .100 kg), and baseline MTX use
(yes/no). A post hoc analysis evaluated efficacy outcomes
among ACR20 nonresponders at week 100.
Safety analyses included data through week 108 for all
patients who received $1 study agent administration. AEs
were reported by randomized treatment group, and the inci-
dence rate per 100 patient-years for select AEs of interest
were reported by actual treatment received (ustekinumab
45 mg or 90 mg).
RESULTS
Patient disposition. A total of 615 patients were random-
ized to placebo (n5 206), ustekinumab 45 mg (n5205), or
ustekinumab 90 mg (n5 204); baseline demographics and
disease characteristics were well-balanced among the groups
(7). At week 16, 58 patients in the placebo group, 36 in the
615 patients randomized
Ustekinumab 45 mg
(n = 205)
Ustekinumab 90 mg
(n = 204)
Placebo*
(n = 206)
162 completed ustekinumab
at week 88
Week 24
15 patients discontinued
study agent
• 8 due to AEs
• 3 lack of efficacy
• 3 withdrew consent
• 1 lost to follow-up
14 patients discontinued
study agent
• 3 due to AEs
• 2 withdrew consent
• 7 lack of efficacy
• 1 lost to follow-up
• 1 other
15 patients discontinued
study agent
• 1 due to AEs
• 4 withdrew consent
• 6 lack of efficacy
• 2 lost to follow-up
• 2 other
158 completed ustekinumab
at week 88
8 patients discontinued
study agent
• 4 due to AEs
• 2 lack of efficacy
• 2 withdrew consent
17 patients discontinued
study agent
• 2 due to AEs
• 7 withdrew consent
• 7 lack of efficacy
• 1 other
22 patients discontinued
study agent
• 5 due to AEs
• 2 withdrew consent
• 6 lack of efficacy
• 5 lost to follow-up
• 4 other
170 completed ustekinumab
at week 88
7 patients discontinued
study agent
• 3 due to AEs
• 1 lack of efficacy
• 2 withdrew consent
• 1 lost to follow-up
15 patients discontinued
study agent
• 5 due to AEs
• 6 withdrew consent
• 3 lack of efficacy
• 1 lost to follow-up
12 patients discontinued
study agent
• 5 withdrew consent
• 5 lack of efficacy
• 1 lost to follow-up
• 1 other
Week 52
Figure 1. Patient disposition through week 108. *5patients randomized to receive placebo at baseline crossed
over to ustekinumab 45 mg at week 16 (early escape) or week 24 (pre-specified crossover); AEs5 adverse events.
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Table 1. Clinical efficacy and radiographic results at week 100*
Placebo to
ustekinumab
45 mg†
Ustekinumab
45 mg 90 mg Combined
Patients randomized, no. 189 205 204 409
Clinical efficacy at week 100
Patients, no. 177 178 176 354
ACR20 111 (62.7) 101 (56.7) 112 (63.6) 213 (60.2)
ACR50 66 (37.3) 69 (38.8) 81 (46.0) 150 (42.4)
ACR70 33 (18.6) 44 (24.7) 39 (22.2) 83 (23.4)
ACR response by baseline weight,
no./total no. (%)
ACR20
#100 kg 88/134 (65.7) 83/135 (61.5) 87/137 (63.5) 170/272 (62.5)
.100 kg 23/43 (53.5) 18/43 (41.9) 25/39 (64.1) 43/82 (52.4)
ACR50
#100 kg 50/134 (37.3) 55/135 (40.7) 65/137 (47.4) 120/272 (44.1)
.100 kg 16/43 (37.2) 14/43 (32.6) 16/39 (41.0) 30/82 (36.6)
ACR70
#100 kg 29/134 (21.6) 36/135 (26.7) 32/137 (23.4) 68/272 (25.0)
.100 kg 4/43 (9.3) 8/43 (18.6) 7/39 (17.9) 15/82 (18.3)
ACR response by baseline MTX use,
no./total no. (%)
ACR20
Yes 57/85 (67.1) 46/86 (53.5) 52/87 (59.8) 98/173 (56.6)
No 54/92 (58.7) 55/92 (59.8) 60/89 (67.4) 115/181 (63.5)
ACR50
Yes 29/85 (34.1) 30/86 (34.9) 35/87 (40.2) 65/173 (37.6)
No 37/92 (40.2) 39/92 (42.4) 46/89 (51.7) 85/181 (47.0)
ACR70
Yes 12/85 (14.1) 19/86 (22.1) 13/87 (14.9) 32/173 (18.5)
No 21/92 (22.8) 25/92 (27.2) 26/89 (29.2) 51/181 (28.2)
DAS28-CRP
Good/moderate response 130 (73.4) 128 (71.9) 135 (76.7) 263 (74.3)
Remission 55 (31.1) 60 (33.7) 61 (34.7) 121 (34.2)
HAQ DI
Change from baseline, median (IQR) 20.38 (20.63, 0.00) 20.25 (20.75, 0.00) 20.38 (20.81, 0.00) 20.25 (20.75, 0.00)
Patients with improvement $0.3 89 (50.3) 85 (47.8) 91 (51.7) 176 (49.7)
Patients with $3% BSA at baseline, no. 136 145 149 294
PASI #3 at week 100,
no./total no. (%)‡
91/122 (74.6) 83/120 (69.2) 99/129 (76.7) 182/249 (73.1)
PASI75, no./total no. (%)‡ 78/122 (63.9) 87/120 (72.5) 92/129 (71.3) 179/249 (71.9)
PASI90, no./total no. (%)‡ 50/122 (41.0) 61/120 (50.8) 67/129 (51.9) 128/249 (51.4)
PASI response by baseline weight,
no./total no. (%)‡
PASI75
#100 kg 54/91 (59.3) 71/90 (78.9) 75/98 (76.5) 146/188 (77.7)
.100 kg 24/31 (77.4) 16/30 (53.3) 17/31 (54.8) 33/61 (54.1)
PASI90
#100 kg 40/91 (44.0) 49/90 (54.4) 52/98 (53.1) 101/188 (53.7)
.100 kg 10/31 (32.3) 12/30 (40.0) 15/31 (48.4) 27/61 (44.3)
PASI response by baseline MTX use,
no./total no. (%)‡
PASI75
Yes 37/59 (62.7) 40/55 (72.7) 40/60 (66.7) 80/115 (69.6)
No 41/63 (65.1) 47/65 (72.3) 52/69 (75.4) 99/134 (73.9)
PASI90
Yes 25/59 (42.4) 29/55 (52.7) 27/60 (45.0) 56/115 (48.7)
No 25/63 (39.7) 32/65 (49.2) 40/69 (58.0) 72/134 (53.7)
(continued)
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45-mg group, and 26 patients in the 90-mg group met the
early escape criteria. After week 52, 36 patients (7.3%) initi-
ated DMARDS, corticosteroids, or MTX or increased base-
line doses of corticosteroids or MTX. Through week 88, 125
patients (20.3%) discontinued the study agent (31 [5.0%]
due to AEs; 40 [6.5%] due to lack of efficacy) (Figure 1).
Table 1. (Cont’d)
Placebo to
ustekinumab
45 mg†
Ustekinumab
45 mg 90 mg Combined
Dactylitis
Patients with dactylitis
at baseline, no.
87 101 99 200
Dactylitis score at baseline,
median (IQR)
5.0 (2.0, 10.0) 4.0 (2.0, 9.0) 4.0 (2.0, 11.0) 4.0 (2.0, 11.0)
Week 100
No. 84 90 86 176
Score improvement, baseline
to week 100, median (IQR)
3.0 (1.0, 7.0) 3.0 (1.0, 6.0) 3.0 (1.0, 8.0) 3.0 (1.0, 6.5)
Percent improvement, baseline
to week 100, median (IQR)
100.0 (32.2, 100.0) 100.0 (66.7, 100.0) 100.0 (60.0, 100.0) 100.0 (65.5, 100.0)
Patients with $1 dactylitis
digit at week 100
31 (36.9) 29 (32.2) 27 (31.4) 56 (31.8)
Enthesitis
Patients with enthesitis at
baseline, no.
128 142 154 296
Enthesitis score at baseline,
median (IQR)
4.0 (2.0, 8.0) 4.0 (2.0, 7.0) 5.0 (2.0, 8.0) 4.0 (2.0, 8.0)
Week 100
No. 118 119 130 249
Score improvement, baseline to
week 100, median (IQR)
2.0 (0.0, 5.0) 2.0 (1.0, 4.0) 3.0 (0.0, 5.0) 3.0 (1.0, 5.0)
Percent improvement, baseline to
week 100, median (IQR)
87.1 (0.0, 100.0) 100.0 (9.1, 100.0) 100.0 (0.0, 100.0) 100.0 (9.1, 100.0)
Patients with enthesitis
at week 100
62 (52.5) 58 (48.7) 61 (46.9) 119 (47.8)
Radiographic progression§
Change from baseline to week 52
in PsA-modified total SHS score
No. 189 205 204 409
Mean6SD 1.4968.18 0.4862.47 0.556 2.97 0.516 2.73
Median (IQR) 0.00 (0.00, 1.00) 0.00 (0.00, 1.00) 0.00 (0.00, 1.00) 0.00 (0.00, 1.00)
Change from baseline to week 100
in PsA-modified total
SHS score
No. 189 205 204 409
Mean6SD 2.266 12.58 0.9563.82 1.186 5.05 1.076 4.47
Median (IQR) 0.00 (0.00, 1.00) 0.00 (0.00, 1.00) 0.00 (0.00, 1.00) 0.00 (0.00, 1.00)
Mean6SD change from baseline to week
100 by weight group and MTX use:
Weight
#100 kg 2.876 14.39 1.0964.25 1.336 5.41 1.216 4.86
.100 kg 0.4062.65 0.5462.05 0.736 3.77 0.636 3.01
MTX use
Yes 1.4565.57 0.9963.76 1.546 5.69 1.276 4.83
No 3.006 16.56 0.9163.89 0.826 4.32 0.866 4.09
Patients with change from baseline in
PsA-modified total SHS score #0
116 (61.4) 133 (64.9) 137 (67.2) 270 (66.0)
* Values are the number (percentage) unless indicated otherwise. ACR20/50/705American College of Rheumatology criteria for 20%/50%/70%
improvement; MTX5methotrexate; DAS285Disease Activity Score in 28 joints; CRP5C-reactive protein; HAQ DI5Health Assessment Question-
naire disability index; IQR5 interquartile range; BSA5 body surface area; PASI75/905 at least 75%/90% improvement in Psoriasis Area and
Severity Index score; PsA5psoriatic arthritis; SHS5modified Sharp/van der Heijde score.
† Patients in the placebo group who did not receive ustekinumab were excluded.
‡ Among patients with $3 BSA affected at baseline.
§ Radiographic results from reading session 2, which included radiographs from weeks 0, 52, and 100.
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Clinical efficacy. At week 100, 62.7% of patients in the
placebo crossover group, 56.7% in the 45-mg group, and
63.6% in the 90-mg group had an ACR20 response (Table 1).
After placebo crossover at week 24, the proportion of patients
with an ACR20 response continued to improve and was sus-
tained through week 100 (Figure 2). ACR50 and ACR70
responses followed a similar pattern and ranged from 37.3–
46.0% and 18.6–24.7%, respectively, at week 100 (Table 1).
The proportions of patients with either a DAS28-CRP
response or remission were maintained from week 52 (7) to
week 100 (Table 1). In all 3 groups, the proportions of patients
with an ACR20/50/70, DAS28-CRP response, DAS28-CRP
remission, or PASI75 at week 100 were greater among patients
who did not qualify for early escape than for those who met
early escape criteria (see Supplementary Table 1, available on
the Arthritis Care & Research web site at http://onlinelibrary.
wiley.com/doi/10.1002/acr.22645/abstract). Although early
escape patients generally had lower response rates, notable
proportions of these patients had an ACR20, DAS28-CRP, or
PASI75 response.
Among patients with dactylitis at baseline, median base-
line dactylitis scores were 5.0 in the placebo group and 4.0 in
both ustekinumab groups (Table 1). At week 100, the 3 treat-
ment groups all had a median score improvement of 3.0 and
a median percent improvement of 100% (Table 1). In the
combined ustekinumab group, the proportions of patients
with $1 digit with residual dactylitis continued to decrease
from week 52 (42.6%; data not shown) through week 100
(31.8%; Table 1). Among patients with enthesitis at baseline,
median baseline enthesitis scores were 4.0 in the placebo
and ustekinumab 45-mg groups and 5.0 in the ustekinumab
90-mg group (Table 1). At week 100, the median score
improvement and percent improvement from baseline,
respectively, were 2.0 and 87.1% in the placebo crossover
group, 2.0 and 100% in the 45-mg group, and 3.0 and 100%
in the 90-mg group (Table 1). The proportions of patients
with residual enthesitis also continued to decrease from
week 52 (55.1%; data not shown) through week 100 (47.8%;
Table 1).
Of the 615 randomized patients, 440 (71.7%) had $3%
BSA affected by psoriasis at baseline (7). At week 100,
63.9%, 72.5%, and 71.3% in the placebo crossover, 45-mg,
and 90-mg groups, respectively, had a PASI75 response,
and 41.0%, 50.8%, and 51.9%, respectively, had a PASI90
response (Table 1). In addition, the vast majority of patients
(69.2–76.7%) had a PASI score#3 at week 100 (Table 1).
ACR20/50/70 and PASI75/90 response rates at week 100
were also evaluated by baseline patient weight (# or
.100 kg) and MTX use (yes/no) (Table 1). Within each
weight group, the proportions of ACR and PASI responders
were maintained over time, and in general, response rates
were numerically greater for patients #100 kg than for
patients .100 kg. At week 100, ACR20/50/70 and PASI75/
90 response rates were similar between the dose groups for
patients #100 kg; however, among patients .100 kg,
response rates were generally higher for patients in the 90-
mg group than in the 45-mg group. In a post hoc analysis by
weight group and early escape status (yes/no), patients
.100 kg tended to have higher ACR and PASI response rates
with the 90-mg dose than with the 45-mg dose, which was
consistent with the overall population. It should be noted
that the relatively small numbers of patients in the sub-
groups limit the interpretation of these post hoc analysis
results (Supplementary Table 2, available on the Arthritis
Care & Research web site at http://onlinelibrary.wiley.com/
doi/10.1002/acr.22645/abstract).
ACR20/50/70 response rates at week 100 were numerical-
ly higher among patients who were not receiving MTX at
baseline than among patients receiving MTX in the same
treatment group (Table 1). A similar trend was observed for
PASI75 and PASI90 responders at week 100 in the 90-mg
group; however, no consistent pattern in PASI response was
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Figure 2. Proportion of patients achieving American College of Rheumatology criteria
for 20% improvement responses over time through week 100. PE5primary end point;
Pbo5placebo; Ust5ustekinumab.
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observed with regard to baseline MTX use in the 45-mg
group.
Improvements from baseline in physical function and
HRQOL were also sustained over time with median
decreases in HAQ DI scores from baseline to week 100 of
0.38, 0.25, and 0.38 in the placebo crossover, 45-mg, and
90-mg groups, respectively (Table 1), and approximately
half of all patients in each group had an improvement in
HAQ DI $0.30 at week 100. Median changes from baseline
to week 100 in SF-36 PCS and MCS scores ranged from 4.8–
6.4 and from 3.0–3.7, respectively, and median changes
from baseline in DLQI score at week 100 were 26.0 in the
placebo crossover group, 25.0 in the 45-mg group, and
26.0 in the 90-mg group (Table 2).
In a post hoc analysis of ACR20 nonresponders at week
100, improvements were observed in skin, soft tissues,
physical function, and HRQOL; however, the magnitude
of improvement was generally lower than that observed in
the overall study population (Supplementary Table 3,
available on the Arthritis Care & Research web site at http://
onlinelibrary.wiley.com/doi/10.1002/acr.22645/abstract).
Radiographic progression. Radiographic progression
through week 100 of PSUMMIT 1 was analyzed using data
from a second reading session of weeks 0, 52, and 100. This
analysis included only patients who received ustekinumab
therapy; therefore, 17 patients who received only placebo
were not included.
The median changes from baseline in total SHS score at
weeks 52 and 100 were 0.0 for all 3 treatment groups (Table 1).
Mean changes from baseline to week 52 in total SHS score
were 0.48 in the 45-mg group and 0.55 in the 90-mg group,
and mean changes from baseline to week 100 were 0.95 and
1.18, respectively (Table 1). At both time points, mean
changes were numerically lower in the ustekinumab groups
than in the placebo crossover group. In the ustekinumab
groups, mean changes in total SHS score from week 52 to
week 100 were similar to those from baseline to week 52
(Figure 3). However, in the placebo crossover group, mean
change from week 52 to 100 in total SHS score was numeri-
cally lower than the change from baseline to week 52 (Figure
3). No consistent pattern was observed for changes in total
SHS score when analyzed by early-escape status (Supple-
mentary Table 1, available on the Arthritis Care & Research
web site at http://onlinelibrary.wiley.com/doi/10.1002/acr.
22645/abstract).
The median change from baseline to week 100 in total SHS
score was 0, regardless of baseline weight group or MTX use
(data not shown), consistent with results of the overall popu-
lation. Mean changes from baseline in total SHS score were
generally smaller for patients.100 kg than for those#100 kg
(Table 1). Radiographic progression did not appear to be
influenced by baseline MTX use (Table 1).
Spondylitis was evaluated through week 24 using the Bath
Ankylosing Spondylitis Disease Activity Index (BASDAI),
and significantly greater proportions of ustekinumab-treated
patients had improvements in BASDAI score at week 24 ver-
sus placebo (7). However, no additional data on axial mani-
festations were collected after week 24.
Adverse events. Through week 108, a total of 598 patients
received $1 ustekinumab injections, and 23 patients (3.8%)
discontinued ustekinumab due to an AE (Table 3). Overall,
the types and rates of AEs through week 108 did not indicate
any disproportional rate increase compared with week 52 (7).
Infections were the most frequent AEs for ustekinumab-
treated patients through week 108 (43.3%); the most common
being nasopharyngitis (n570, 11.7%, 10.41 per 100 patient-
years [95% confidence interval (95% CI)] 8.56, 12.55) and
upper respiratory tract infection (n5 60, 10.0%, 7.48 per 100
patient-years [95% CI 5.92, 9.32]). AEs through week 108
were not affected by baseline concomitant MTX use (data not
shown). There were no reports of anaphylactic shock, serum
sickness–like reactions, or deaths.
Among all ustekinumab-treated patients, 58 (9.7%) had
$1 serious AE (SAE) through week 108. Most were
singular events, with the exceptions of myocardial infarc-
tion (n5 5), osteoarthritis (n53), cholecystitis/cholecystitis
acute (n5 3), dehydration (n5 2), and depression (n5 2).
The proportion of patients with $1 serious infection was
low (45-mg group, 2.4%; 90-mg group, 2.5%) (Table 3); the
incidence (95% CI) of serious infections per 100 patient-
years was 0.64 (0.18, 1.64) among patients receiving usteki-
numab 45 mg and 2.30 (1.10, 4.24) among those receiving
ustekinumab 90 mg. The higher rate reported in the 90-mg
group was mainly driven by 2 patients who reported multi-
ple events. No serious opportunistic infections or cases of
active tuberculosis occurred.
Table 2. Changes from baseline to week 100 in health-related quality of life measures*
Placebo to
ustekinumab
45 mg†
Ustekinumab
45 mg 90 mg Combined
Patients randomized, no. 189 205 204 409
Change from baseline to week 100
SF-36 PCS score 4.8 (0.0, 12.7) 5.1 (0.0, 13.7) 6.4 (0.0, 14.2) 5.3 (0.0, 14.1)
SF-36 MCS score 3.3 (0.0, 11.6) 3.0 (21.0, 9.3) 3.7 (20.6, 10.7) 3.2 (20.8, 9.9)
DLQI score 26.0 (211.0, 21.0) 25.0 (211.5, 21.0) 26.0 (211.0, 22.0) 25.0 (211.0, 22.0)
* Values are the median (interquartile range) unless indicated otherwise. SF-365Short Form 36 health survey; PCS5physical component summa-
ry; MCS5mental component summary; DLQI5Dermatology Life Quality Index.
† Patients in the placebo group who did not receive ustekinumab were excluded.
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Through week 108, 7 events were reported as major
adverse cardiovascular events (incidence per 100 patient-
years [95% CI] for 45-mg group: 0.96 [0.35, 2.10]; for
90-mg group: 0.23 [0.01, 1.28]). Three (nonfatal stroke:
n5 1; myocardial infarction: n5 2) occurred before week
52 (7). After week 52, myocardial infarction occurred in 3
patients (45 mg: n51; 90 mg: n5 1; 45 mg to 90 mg:
n51), and 1 patient (45 mg) had an ischemic stroke. All
patients who experienced a major adverse cardiovascular
event had $2 cardiovascular risk factors other than PsA
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Figure 3. Mean change in psoriatic arthritis–modified total Sharp/van der Heijde score (SHS)
from week 0 to week 52 (A), and from week 52 to week 100 (B), showing interquartile ranges
(shaded bars), means (solid line), and medians (broken lines). Mean values presented above
graphs for each group. *5patients who met early escape criteria at week 16 or crossed over to
ustekinumab 45 mg at week 24.
Table 3. Adverse events (AEs) through week 108*
Placebo to
45 mg†
Ustekinumab
45 mg‡
Ustekinumab
90 mg
All
ustekinumab
Patients treated with ustekinumab, no. 189 205 204 598
Mean duration of followup, no. weeks 79.9 96.8 98.0 91.9
Patients with $1 AE 117 (61.9) 158 (77.1) 148 (72.5) 423 (70.7)
Infections 66 (34.9) 93 (45.4) 100 (49.0) 259 (43.3)
Patients who discontinued due to AEs 4 (2.1) 11 (5.4) 8 (3.9) 23 (3.8)
Common ($5%) AEs
Nasopharyngitis 15 (7.9) 25 (12.2) 30 (14.7) 70 (11.7)
Upper respiratory tract infection 18 (9.5) 22 (10.7) 20 (9.8) 60 (10.0)
Hypertension 9 (4.8) 15 (7.3) 17 (8.3) 41 (6.9)
Arthralgia 9 (4.8) 15 (7.3) 15 (7.4) 39 (6.5)
Psoriatic arthropathy 10 (5.3) 8 (3.9) 14 (6.9) 32 (5.4)
Patients with $1 SAE 15 (7.9) 26 (12.7) 17 (8.3) 58 (9.7)
AEs of interest
Patients with $1 serious infection 1 (0.5) 5 (2.4) 5 (2.5) 11 (1.8)
Patients with $1 MACE 2 (1.1) 4 (2.0) 1 (0.5) 7 (1.2)
Malignancies
B cell lymphoma 0 1 (0.5) 0 1 (0.2)
Basal cell carcinoma 0 0 1 (0.5) 1 (0.2)
Renal cell carcinoma 1 (0.5) 0 0 1 (0.2)
Squamous cell carcinoma 0 0 1 (0.5) 1 (0.2)
Deaths 0 0 0 0
* Values are the number (percentage) unless indicated otherwise. SAE5 serious AE; MACE5major adverse cardiovascular event.
† Includes all patients who received at least 1 injection of ustekinumab after early escape at week 16 or crossover at week 24.
‡ Includes all patients randomized to the 45-mg group, including those who early escaped at week 16 to receive ustekinumab 90 mg.
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(i.e., obesity, history of smoking, hypertension, hyperlip-
idemia, diabetes mellitus, or previous stroke).
Four malignancies were reported. The incidence (95%
CI) of total malignancies per 100 patient-years was 0.32
(0.04, 1.16) for patients receiving ustekinumab 45 mg, and
0.46 (0.06, 1.67) for patients receiving ustekinumab 90 mg.
One patient (45-mg group) was diagnosed with B cell lym-
phoma and discontinued study treatment. Another patient
(placebo to 45 mg) was diagnosed with renal cell carcino-
ma approximately 11 weeks after the week-88 ustekinu-
mab administration. Two patients were diagnosed with
nonmelanoma skin cancer (both receiving 90 mg): squa-
mous cell carcinoma in one patient approximately 11
weeks after the week-88 ustekinumab administration and
basal cell carcinoma in another patient at week 88.
A total of 4,618 ustekinumab injections (45 mg: n5 2,743;
90 mg: n5 1,875) were administered, and 17 (total 0.4%;
45 mg: 4 [0.1%]; 90 mg: 13 [0.7%]) were associated with an
injection site reaction. All injection site reactions were mild,
and none resulted in treatment discontinuation.
No clear pattern of changes in hematology parameters or
other laboratory measurements over time was discerned
for any treatment group. The proportions of patients with
markedly abnormal post-baseline values were generally
low and comparable between the ustekinumab doses.
Pharmacokinetics and immunogenicity. Serum usteki-
numab concentrations increased in a dose-proportional man-
ner. At week 88, the mean steady-state trough serum uste-
kinumab concentration was 0.56 mg/ml among patients in the
45-mg group who did not enter early escape and 1.02 mg/ml
among patients in the 90-mg group, a difference of approxi-
mately 2 fold. Serum ustekinumab concentrations tended to
be lower among patients.100 kg than in patients#100 kg.
Through week 108, a total of 49 of 591 patients (8.3%)
tested positive for antibodies to ustekinumab. The inci-
dence of antibodies to ustekinumab was similar between
the 2 doses, but was lower among patients receiving con-
comitant MTX (n5 13 of 287, 4.5%) compared with those
not receiving MTX (n5 36 of 304, 11.8%). Patients who
tested positive for antibodies to ustekinumab had lower
mean serum ustekinumab concentrations than patients
who tested negative. The proportions of patients with an
ACR20 or ACR50 response tended to be numerically lower
for patients who were positive for antibodies to ustekinu-
mab compared with those who were negative (Supple-
mentary Table 4, available on the Arthritis Care &
Research web site at http://onlinelibrary.wiley.com/doi/
10.1002/acr.22645/abstract); similar results were observed
for PASI75 and PASI90 (Supplementary Table 5).
DISCUSSION
The PSUMMIT 1 study was a phase 3, double-blind placebo-
controlled trial to evaluate the efficacy and safety of usteki-
numab treatment through 2 years in adult patients with
active PsA, despite prior DMARD or NSAID therapy.
Through the placebo-controlled period of PSUMMIT 1
(weeks 0–24), ustekinumab-treated patients had significantly
greater reductions in the clinical signs and symptoms of both
joint and skin disease, greater improvements in physical
function, and less radiographic progression when compared
with those receiving placebo (7,8). These responses were
maintained through 1 year (7,8), and the current analyses fur-
ther demonstrate the maintenance of improvements in clini-
cal efficacy and radiographic measures through 2 years of
treatment with ustekinumab.
Approximately 20% of patients discontinued treatment
prior to week 88, which was comparable to discontinuation
rates for trials of other biologic therapies (19,20). At week
100, a high level of response was observed across the treat-
ment groups for both joint and skin disease activity meas-
ures (ACR20/50/70 ranges: 57–64%, 37–46%, and 19–25%,
respectively, and PASI75/90 ranges: 64–73% and 41–52%,
respectively). Improvements in dactylitis, enthesitis, physi-
cal function, and HRQOL were also maintained through
week 100. Early-escape patients consistently had lower
response rates than patients in the same treatment group
who did not meet the early escape criteria. Despite this,
modest proportions of these patients experienced clinically
meaningful improvements for some outcomes.
As noted previously, the time to reach a maximum ACR
response may be longer with ustekinumab than with anti-
TNF therapies, but in general, the proportions of patients
reaching an ACR response at week 52 of the PSUMMIT 1
trial were consistent with those observed with anti-TNF
agents (7). In a head-to-head psoriasis clinical study, uste-
kinumab demonstrated superior efficacy in achieving
PASI responses compared with etanercept during the first
12 weeks of treatment (21). The current analysis further
indicated that the proportions of patients who were
ACR20/50/70 responders or PASI75/90 responders at
week 100 also appeared to be consistent with results from
trials of anti-TNF therapies in PsA (19,20).
Patients who did not have an ACR20 response at week
100 generally experienced meaningful improvements in
skin, dactylitis, enthesitis, physical function, and HRQOL
outcomes at week 100. Approximately 50% had $3%
BSA with psoriasis involvement at baseline; therefore,
skin improvement alone cannot fully explain their study
continuation. The totality of improvements observed in
these outcomes, along with some improvements in tender
and swollen joint counts that did not exceed the 20%
threshold for both at individual visits, may help explain
why these patients remained in the trial and continued
ustekinumab treatment through 2 years.
In the current analysis of patients from PSUMMIT 1, a
biologic-naive population, inhibition of structural damage
with ustekinumab therapy was maintained through week
108. In the 45-mg and 90-mg groups, radiographic progres-
sion was similar from baseline to week 52 and from week 52
to week 100, indicating that inhibition of radiographic pro-
gression through week 52 was maintained from week 52 to
100. Additionally, mean changes from baseline through
week 100 in both the 45-mg and 90-mg groups were less than
or comparable to the mean change in the placebo group
observed during the placebo-controlled period (weeks 0–24)
(8), further supporting the inhibition effect during the sec-
ond year of treatment.
Throughout the trial, patients #100 kg at baseline gener-
ally had numerically greater ACR and PASI response rates
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than did patients .100 kg receiving the same dose; among
patients .100 kg, response rates were higher in the 90-mg
group than in the 45-mg group. In the radiographic analy-
sis, patients .100 kg generally had less progression than
did those#100 kg, consistent with previous research show-
ing an association of high body mass index with less radio-
graphic progression among patients with rheumatoid
arthritis (22). Ustekinumab was efficacious irrespective of
MTX use, although the proportions of patients with an
ACR20/50/70 response tended to be numerically greater
among patients not receiving baseline MTX compared with
those receiving MTX. No consistent pattern was observed
from similar analyses of PASI responses. However, as is the
case with most recent PsA studies, the study design does
inform as to whether combination therapy with MTX may be
of benefit, and if so, to what extent and for which outcomes.
Safety findings through week 108 were consistent with
those observed through week 52 (7), and the known safety
profile of ustekinumab in patients with psoriasis (23).
There was no apparent dose effect for the rates and types of
AEs or SAEs. All injection site reactions were mild, and
none led to study discontinuation. The incidence of serious
infections was low and similar across treatment groups.
Eleven patients (1.8%) had a serious infection, and there
was no apparent increase in incidence with longer usteki-
numab exposure. There were no cases of active tuberculo-
sis or serious opportunistic infections.
Seven major adverse cardiovascular events occurred, all
in patients with $2 preexisting cardiovascular risk factors.
In addition, 4 malignancies were reported. Ustekinumab
treatment did not appear to affect hematology or chemistry
laboratory values. There were no anaphylactic reactions,
serum sickness–like reactions, or deaths. No apparent effect
of concomitant MTX use on AEs was observed.
Approximately 8% of ustekinumab-treated patients were
positive for antibodies to ustekinumab, with a lower inci-
dence among patients receiving concomitant MTX com-
pared with those not receiving MTX. In both dose groups,
mean serum ustekinumab concentrations were lower in
patients who tested positive for antibodies to ustekinumab
than in patients who tested negative. Patients who tested
positive for antibodies to ustekinumab tended to have lower
ACR response rates; however, the presence of these antibod-
ies did not preclude a clinical response to ustekinumab,
consistent with a previous analysis (24).
Interpretation of the findings through week 108 of
PSUMMIT 1 is limited by the lack of a placebo control group
after week 24. Although ACR response rates seemed higher
in patients not receiving MTX at baseline versus those receiv-
ing MTX, this trial was not designed to assess such differ-
ences. Furthermore, efficacy for patients who early escaped
from 45 mg to 90 mg was analyzed within the 45-mg group
through week 88, which may have undermined the dose
responses observed between the dose groups.
In summary, these results demonstrated the mainte-
nance of the effects of ustekinumab 45 mg and 90 mg every
12 weeks on clinical efficacy, radiographic progression,
and HRQOL through 2 years, with no unexpected AEs.
This study demonstrated a favorable benefit risk profile of
ustekinumab treatment in patients with active PsA.
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